Global Hepatitis C Market 2014-2018 Published: September 2014
No. of Pages: 104
Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule enveloped by a lipid bilayer. Hepatitis C can lead to acute infection or chronic infection. Nearly 80 percent of the infected individuals suffering from acute infection are asymptomatic. Symptoms manifested in the rest include nausea, dark urine, fever, anorexia, gray-colored faces, abdominal pain, and joint pain. Nearly 20 percent of infected individuals develop jaundice, which is characterized by the yellowing of skin and eyes. Nearly 15-45 percent of acutely infected individuals recover from the infection spontaneously within the first six months of infection. This happens because the immune system mediated the clearance of the virus from the body. The remaining 55-85 percent of infected individuals who fail to clear the virus within six months develop chronic hepatitis C phase. Chronic infection can lead to mild-to-moderate symptoms or chronic symptoms such as liver fibrosis, liver cirrhosis, and hepatic cancer. The World Health Organization (WHO) estimates that globally, 130-150 million people suffer from chronic hepatitis B. It also reported that every year 350,000-500,000 infected individuals die because of hepatitis C-related hepatic disorders. Currently, there is no vaccine for the prevention of hepatitis C infection; however, various treatment options for hepatitis C infection are available. TechNavio's analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus. TechNavio's report, the Global Hepatitis C Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis C market landscape and its growth prospects in the
coming years. The report includes a discussion of the key vendors operating in this market. Key Regions • Americas • APAC • EMEA Key Vendors • F. Hoffmann-La Roche • Gilead Sciences • Johnson & Johnson • Merck • Vertex Pharmaceuticals Other Prominent Vendors • Abbvie • Achillion Pharmaceuticals • Bristol-Myers Squibb • Mitsubishi Tanabe Pharma • Novartis Market Driver • Increase in Injection Drug Users • For a full, detailed list, view our report Market Challenge • Side-effects of Current Therapy • For a full, detailed list, view our report Market Trend • Emergence of Interferon-free Therapies • For a full, detailed list, view our report
Key Questions Answered in this Report • What will the market size be in 2018 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors?
Detailed report at: http://www.reportsandintelligence.com/globalhepatitis-c-2014-2018-reports-market
Table of Content 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 03.1 Market Overview 03.2 Product Offerings 04. Market Research Methodology 04.1 Market Research Process 04.2 Research Methodology 05. Introduction 06. Disease Overview 06.1 Mode of Infection Transmission 06.2 Geographical Distribution 06.3 Screening 06.4 Treatment 06.4.1 WHO Guidelines 06.4.2 AASLD guidelines 07. Market Landscape 07.1 Market Overview 07.2 Market Size and Forecast 07.3 Five Forces Analysis 08. Key Marketed Drugs for Treatment of Chronic Hepatitis C 09. Market Segmentation by MOA 09.1 Virus-specific Agents
09.1.1 Polymerase Inhibitors 09.1.2 Protease Inhibitors 09.2 Non-specific Agents 09.2.1 IFN-based Drugs 09.2.2 Others 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 18.1 Competitive Scenario 18.1.1 Key News 18.1.2 Mergers and Acquisitions 18.2 Market Share Analysis 2013 18.2.1 Roche 18.2.2 Merck 18.2.3 Johnson and Johnson 18.2.4 Vertex Pharmaceuticals 18.2.5 Gilead 18.3 Other Prominent Vendors 19. Key Vendor Analysis 19.1 F. Hoffmann La Roche 19.1.1 Key Facts 19.1.2 Business Overview 19.1.3 Business Segmentation by Revenue 2013 19.1.4 Business Segmentation by Revenue 2012 and 2013 19.1.5 Geographical Segmentation by Revenue 2013 19.1.6 Business Strategy 19.1.7 Recent Developments 19.1.8 SWOT Analysis 19.2 Gilead 19.2.1 Key Facts 19.2.2 Business Overview 19.2.3 Geographical Segmentation by Revenue 2013 19.2.4 Recent Developments 19.2.5 SWOT Analysis
19.3 Johnson & Johnson 19.3.1 Key Facts 19.3.2 Business Overview 19.3.3 Business Segmentation by Revenue 2013 19.3.4 Business Segmentation by Revenue 2012 and 2013 19.3.5 Geographical Segmentation by Revenue 2013 19.3.6 Business Strategy 19.3.7 Recent Developments 19.3.8 SWOT Analysis 19.4 Merck 19.4.1 Key Facts 19.4.2 Business Overview 19.4.3 Business Segmentation by Revenue 2013 19.4.4 Business Segmentation by Revenue 2012 and 2013 19.4.5 Sales by Geography 19.4.6 Business Strategy 19.4.7 Key Developments 19.4.8 SWOT Analysis 19.5 Vertex Pharmaceuticals 19.5.1 Key Facts 19.5.2 Business Overview 19.5.3 Business Segmentation by Revenue 2013 19.5.4 Business Segmentation by Revenue 2012 and 2013 19.5.5 Geographical Segmentation by Revenue 2013 19.5.6 Business Strategy 19.5.7 Recent Developments 19.5.8 SWOT Analysis 20. Other Reports in this Series
Get detailed TOC at: http://www.reportsandintelligence.com/globalhepatitis-c-2014-2018-reports-market/table-of-contents
Contact Us: Cathy Viber 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States Direct: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 Fax: +1 (855) 550-5975 Email: sales@reportsandintelligence.com Web: http://www.reportsandintelligence.com LinkedIn: http://www.linkedin.com/company/reports-andintelligence